{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Aceburic acid is the acetyl ester of gamma-hydroxybutyrate (GHB), it has analgesic effects as a prodrug to GHB. GHB is used medically as an anesthetic as well as a treatment for several neurologically affecting diseases.
Status:
Investigational
Source:
NCT00244322: Phase 2 Interventional Completed Alzheimer's Disease
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Semagacestat (LY-450139) was a gamma secretase inhibitor being developed as a treatment for Alzheimer's disease by Eli Lilly. It was hoped that the drug would help to delay the onset of severe Alzheimer's disease, and thereby help preserve cognitive and executive functioning and in turn improve patient quality of life. Semagacestat (LY-450139) is designed to inhibit gamma secretase, an enzyme that is involved in the cleavage of APP to beta-amyloid. By decreasing production of beta-amyloid, it is hoped that gamma secretase inhibitors will exert a disease-modifying effect in Alzheimer's disease and thus slow or halt the destruction of nerve cells – the final stage in the amyloid cascade hypothesis. In March 2008 semagacestat (LY-450139) advanced to Phase III development, where it was evaluated in the IDENTITY (Interrupting Alzheimer's Dementia by EvaluatiNg Treatment of AmyloId PaThologY) trial, the first Phase III trial for this new anti-dementia drug. In August 2010, Eli Lilly announced its decision to halt the development of Semagacestat. The decision was taken after analysing the preliminary results of the second Phase III clinical trial of the drug, which indicated that semagacestat failed to slow disease progression. The drug, in fact, worsened cognition and the ability to perform day-to-day activities.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cicaprost is a prostacyclin receptor (IP) agonist and orally active prostacyclin analog with potent systemic and pulmonary vasodilatation and anti-inflammatory activity. In preclinical models, Cicaprost treatment largely prevented the hypercholesterolemia-related impairment of coronary vasodilation and nitric oxide release in Isolated Langendorff-hearts. Cicaprost inhibits proinflammatory chemokines production not only from lipopolysaccharides (LPS) or (tumor necrosis factor-alpha) induced primary human monocyte-derived macrophages but also from LPS-stimulated monocyte-derived dendritic cells. Besides that Cicapost strongly inhibits lymph node and organ metastases of spontaneously metastasizing mammary tumors with a mode of action different from cytostatic or antihormonal drugs. In animal models, Cicaprost prevents metastasis if given continuously from the day of tumor implantation, and is effective in reducing metastasis if treatment is begun following surgical removal of the primary tumor when micrometastases are already present. Clinical trials of Cicaprost in healthy male volunteers demonstrate significant anti-platelet and vasodilatory effects.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cartasteine is thioether derivative patented by Beijing Beipeng Technology Co. for resisting platelet aggregation and preventing or treating cardiovascular and cerebrovascular diseases
Status:
Investigational
Source:
NCT00503360: Phase 1 Interventional Completed Ocular Hypertension
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00806338: Phase 1 Interventional Completed Diabetes Mellitus
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Trodusquemine (MSI-1436) is a "first-in-class" highly selective non-competitive, allosteric inhibitor of PTP1B that can cross the blood-brain barrier to suppress feeding and promote insulin sensitivity and glycemic control. Trodusquemine is a naturally occurring cholestane that can be purified from the liver of the dogfish shark, Squalus acanthias, but it can also be manufactured synthetically by a fairly laborious process that requires several weeks. Trodusquemine has potential hypoglycemic, anti-diabetic, anti-obesity, and antineoplastic activities. Upon administration, trodusquemine selectively targets and inhibits PTP1B, thereby preventing PTP1B-mediated signaling. This prevents the dephosphorylation of the insulin receptor, which improves insulin signaling and insulin sensitivity, and decreases blood glucose levels. In susceptible cancer cells, inhibition of PTP1B causes a reduction of tumor cell proliferation.
Status:
Investigational
Source:
NCT00659490: Phase 2 Interventional Completed Pain
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:cyacetacide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Cyacetacide is a biochemical used in the past as an anti-tuberculosis agent and currently used in Russia to for the treatment of various forms of tubercular lesions of the eye: keratitis, scleritis, uveitis, chorioretinitis, tuberculosis-allergic diseases and eye diseases of non-tubercular origin. Cyacetacide has also been used to derive compounds that may have antitumor properties.
Status:
Investigational
Source:
NCT01320553: Phase 2 Interventional Completed Allergic Conjunctivitis
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:fencarbamide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Phencarbamide is an anti-spasmodic and anticholinergic drug used during parturition. It has a specific antispasmodic action on the smooth muscle, both directly like papaverine and through the autonomic nervous system (atropine effect). It has also an analgesic effect of its own. Side-effects generally associated with the atropine group of drugs.
